LivaNova PLC Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by LivaNova PLC on August 5, 2016, regarding events occurring on August 3 and August 4, 2016. The filing details the formalization of a separation agreement and a subsequent consulting arrangement with Mr. Michel Darnaud, a named executive officer, who previously announced his retirement for the first quarter of 2017.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation and contractual arrangements.
Material Changes and Compensation Details
The filing discloses the terms of a Termination and Settlement Agreement and a Consulting Agreement with Mr. Darnaud:
- Separation Payment: Mr. Darnaud is entitled to 24 months of base salary (€915,960) and two years of annual bonus (€567,895), totaling €1,483,855. These amounts are based on the 2015 Amendment to his employment contract and will be paid in two installments.
- Mandatory Statutory Payments: Under French law, he will receive a mandatory retirement payment of €98,029, plus payments for unused holidays, a prorated "13th month" salary, and any earned 2016 Annual Executive Bonus.
- Consulting Agreement: Effective August 4, 2016, Mr. Darnaud will provide transition and litigation support services. The Company will pay €120,000 in 48 equal monthly installments, commencing within 10 business days of his termination.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk disclosed relates to the execution of the transition of the Cardiac Surgery business management to Mr. Darnaud's successors.
Key Facts for Investor Verification
- Total immediate separation compensation (salary and bonus) equals €1,483,855.
- Additional consulting fees of €120,000 will be paid over 48 months.
- Mr. Darnaud's retirement is scheduled for the first quarter of 2017.
- The agreements are governed by French law and involve LivaNova France SAS, a wholly-owned subsidiary.